HALO Stock Analysis: Buy, Sell, or Hold?
HALO - Halozyme Therapeutics, Inc.
$108.17
2.05 (1.93%)
▲
5d:
+9.64%
30d:
+33.81%
90d:
+57.87%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When HALO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: HALO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: HALO shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$145.67
Based on 12.6% avg growth
INTRINSIC VALUE TODAY
$90.45
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HALO is currently trading at $108.17, which is considered extended relative to its 30-day fair value range of $77.33 to $100.46. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.4) compared to its historical average (7.8). At these levels, the market is pricing in 10.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is approaching resistance at $108.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HALO scores 6/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is approaching resistance at $108.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HALO scores 6/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$77.33 -
$100.46
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.7%
Protect Your Profits
HALO is technically overbought (RSI 78). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.7% above its trading range)
- BEARISH: Weak technical setup (6/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($99.56)
- NEUTRAL: Trading at premium valuation - market expects 10.3% growth which is achievable
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$77.33 -
$100.46
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$98.13
Resistance Level
$108.49
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.41
Wall Street Target
$99.56
(-8.0%)
Revenue Growth (YoY)
47.7%
Earnings Growth (YoY)
42.9%
Profit Margin
24.9%
Valuation Premium vs History
+10.3% premium
PE vs Historical
10.4 vs 7.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+10.3%
(market-implied from PE analysis)
1-Year Target
$119.31
(+10%)
2-Year Target
$131.60
(+22%)
3-Year Target
$145.16
(+34%)
3-Yr Target (if PE normalizes)
(PE: 10→8)
PE COMPRESSION
$108.78
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 21.2%)
$371.14
(+243%)
Base:
(SPY PE: 10.4, Growth: 21.2%)
$192.46
(+78%)
Bear:
(PE: 7.8, Growth: 21.2%)
$144.24
(+33%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 31.58 | Current EPS (TTM): $3.36
Bull Case
$233.46
(+116%)
Analyst growth 100.0%, PE expands to 34.7
Base Case
$212.24
(+96%)
Market implied 100.0%, PE stable at 31.6
Bear Case
$72.16
(-33%)
Severe decline -20.0%, PE contracts to 26.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 6:58 PM ET
Data refreshes hourly during market hours. Next update: 7:58 PM
Data refreshes hourly during market hours. Next update: 7:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HALO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Helen Torley
SELL
10000 shares
2026-04-06
Helen Torley
SELL
20000 shares
2026-04-02
Cortney Caudill
SELL
8857 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
Advanced HALO Option Strategies
Professional options setups generated by AI based on today's HALO price and gamma walls.
